Basilea Pharmaceutica AG (BSLN) — Cash Flow Quality Index
Basilea Pharmaceutica AG (BSLN) has a Cash Flow Quality Index of 1.60x as of December 2025. Operating cash flow of CHF39.03 Million exceeds net income of CHF24.44 Million, indicating high earnings quality where cash backs reported profits. Explore BSLN long-term investment intensity to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Basilea Pharmaceutica AG Cash Flow Quality Index (2010–2025)
Historical Cash Flow Quality Index for Basilea Pharmaceutica AG across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Basilea Pharmaceutica AG tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Basilea Pharmaceutica AG (2010–2025)
Year-by-year earnings quality comparison for Basilea Pharmaceutica AG. For live market cap and the full company financial profile, see BSLN market cap overview.
| Year | Quality Index | Operating CF (CHF) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.54x | CHF62.09 Million | CHF40.24 Million | ▲ +61.0% |
| 2024 | 0.96x | CHF74.36 Million | CHF77.59 Million | ▼ -29.7% |
| 2023 | 1.36x | CHF14.24 Million | CHF10.45 Million | ▲ +134.6% |
| 2022 | 0.58x | CHF7.06 Million | CHF12.15 Million | ▼ -41.4% |
| 2010 | 0.99x | CHF106.64 Million | CHF107.56 Million | — |